Skip to Content
Merck
  • Engineering Scheffersomyces stipitis for fumaric acid production from xylose.

Engineering Scheffersomyces stipitis for fumaric acid production from xylose.

Bioresource technology (2015-04-12)
Liang Wei, Jiao Liu, Haishan Qi, Jianping Wen
ABSTRACT

In this work, Scheffersomyces stipitis, the yeast with excellent xylose-utilizing ability, was firstly engineered for fumaric acid production from xylose with the heterologous reductive pathway from Rhizopus oryzae FM19, and 1.86g/L fumaric acid was produced by the initial strain PSRPMF under the oxygen-limited condition. Furthermore, three strategies were performed to improve the fumaric acid production, including increasing the reductive pathway activity by codon optimization, blocking the fumaric acid conversion in tricarboxylic acid cycle by knocking out the native fumarases, and improving the fumaric acid transportation by overexpressing heterologous transporter. Finally, the strain PSYPMFfS was obtained and the fumaric acid titer reached to 4.67g/L, significantly increased by 37.92-fold than that of the control strain PSPYSS. It was indicated that the S. stipitis was a promising platform for fumaric acid production from xylose.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Xylitol, ≥99% (GC)
Supelco
Xylitol, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Xylitol
Xylitol, European Pharmacopoeia (EP) Reference Standard
USP
Xylitol, United States Pharmacopeia (USP) Reference Standard
Xylose, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
D-(+)-Xylose, BioUltra, ≥99.0% (sum of enantiomers, HPLC)
Sigma-Aldrich
D-(+)-Xylose, ≥99%
Sigma-Aldrich
D-(+)-Xylose, ≥99% (GC)
Sigma-Aldrich
D-(+)-Xylose, ≥99% (GC), BioXtra